Alle Storys
Folgen
Keine Story von Norgine mehr verpassen.

Norgine

UK High Court of Justice Rules Endocuff® and Endocuff Vision® Patents and Design Rights to be Valid and Infringed

Amsterdam (ots/PRNewswire)

Arc Medical Design Limited, a subsidiary of Norgine B.V., today announced that the High Court of Justice England and Wales, Patents Court ruled that ENDOCUFF® and ENDOCUFF VISION® UK national and UK(EP) patents (as amended) are valid and infringed by Cantel's AmplifEYE® endoscopic device, and key design rights are valid and infringed by AmplifEYE®. The patent and design rights had been challenged by Cantel Medical (UK) Limited and Cantel (UK) Limited.

(Logo: http://mma.prnewswire.com/media/597589/Norgine_Logo.jpg )

Peter Martin, COO of Norgine and Chair of the Arc Medical Design Limited Board said: "We welcome the judgement and our resounding success, recognising the strong protection for both ENDOCUFF® and ENDOCUFF VISION®. This decision validates our confidence in the intellectual property portfolio protecting our products. We will always vigorously defend our intellectual property and will initiate legal proceedings where appropriate."

ENDOCUFF VISION® is a single use device attached at the end of the colonoscope that gives an optimal view of the entire colon by retracting folds during withdrawal.

Notes to Editors:

About the UK Case No. HP-2016-000047

On Friday 23 February 2018 the High Court of Justice England and Wales, Patents Court ruled that:Arc Medical Design Limited won on all counts:

- Arc Medical Design Limited's ENDOCUFF and ENDOCUFF VISION UK 
  national patent 2478081 and UK(EP) patent 2575590, as amended, are 
  valid and infringed;
- its ENDOCUFF VISION Registered Community Design 002523191-0001 is 
  valid and infringed, its ENDOCUFF Registered Community Design 
  001856121-0001 is valid but not infringed; and
- its UK unregistered design rights in ENDOCUFF and ENDOCUFF VISION 
  will be infringed from the date of the judgment.
- The judgment is for the UK market.

View the full media release on http://www.norgine.com/media

Media Contact:

Isabelle Jouin, T: +44 (0)1895 453643

Follow us @norgine

Weitere Storys: Norgine
Weitere Storys: Norgine
  • 11.05.2017 – 13:16

    Merus Labs and Norgine Enter Into a Definitive Arrangement Agreement

    Toronto and Amsterdam (ots/PRNewswire) - - Norgine to acquire all outstanding shares of Merus for $1.65 per share in cash Merus Labs International Inc. ("Merus" or the "Company") TSX: MSL, NASDAQ: MSLI and Norgine B.V. ("Norgine") announced today that they have entered into a definitive agreement (the "Arrangement Agreement") under which Norgine will acquire all of the issued and outstanding common shares of Merus for ...

  • 24.05.2013 – 12:02

    PBAC Approves XIFAXAN® (Rifaxamin a) 550 mg Cost Effectiveness in Australia

    London (ots/PRNewswire) - Norgine today announced that the Australian assessment body the Pharmaceutical Benefits Advisory Committee (PBAC) has recommended the use of XIFAXAN 550 mg in the prevention of the recurrence of hepatic encephalopathy (HE) where other treatments have failed or are contraindicated; a potentially life-threatening neuropsychiatric condition ...